Logo image of OBIO

ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Price, Quote, News and Overview

NASDAQ:OBIO - Nasdaq - US68572M1062 - Common Stock - Currency: USD

2.46  +0.04 (+1.65%)

After market: 2.5299 +0.07 (+2.84%)

OBIO Quote, Performance and Key Statistics

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (5/7/2025, 8:24:41 PM)

After market: 2.5299 +0.07 (+2.84%)

2.46

+0.04 (+1.65%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High8.87
52 Week Low2.37
Market Cap94.24M
Shares38.31M
Float25.12M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-09 2025-05-09/amc
IPO08-04 2020-08-04


OBIO short term performance overview.The bars show the price performance of OBIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

OBIO long term performance overview.The bars show the price performance of OBIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of OBIO is 2.46 USD. In the past month the price decreased by -11.83%. In the past year, price decreased by -47.77%.

ORCHESTRA BIOMED HOLDINGS IN / OBIO Daily stock chart

OBIO Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 28.02 232.31B
ISRG INTUITIVE SURGICAL INC 70.18 192.17B
BSX BOSTON SCIENTIFIC CORP 38.81 155.01B
SYK STRYKER CORP 30.65 146.59B
MDT MEDTRONIC PLC 15.57 106.66B
BDX BECTON DICKINSON AND CO 11.86 47.99B
EW EDWARDS LIFESCIENCES CORP 28.86 44.12B
IDXX IDEXX LABORATORIES INC 42.69 39.43B
RMD RESMED INC 26.95 35.88B
DXCM DEXCOM INC 50.52 32.68B
GEHC GE HEALTHCARE TECHNOLOGY 14.96 31.51B
PHG KONINKLIJKE PHILIPS NVR- NY 15.41 22.46B

About OBIO

Company Profile

OBIO logo image Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. The company is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The company is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Company Info

ORCHESTRA BIOMED HOLDINGS IN

150 Union Square Drive

New Hope PENNSYLVANIA US

Employees: 56

OBIO Company Website

OBIO Investor Relations

Phone: 16463439298

ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ

What is the stock price of ORCHESTRA BIOMED HOLDINGS IN today?

The current stock price of OBIO is 2.46 USD. The price increased by 1.65% in the last trading session.


What is the ticker symbol for ORCHESTRA BIOMED HOLDINGS IN stock?

The exchange symbol of ORCHESTRA BIOMED HOLDINGS IN is OBIO and it is listed on the Nasdaq exchange.


On which exchange is OBIO stock listed?

OBIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ORCHESTRA BIOMED HOLDINGS IN stock?

13 analysts have analysed OBIO and the average price target is 15.15 USD. This implies a price increase of 516.02% is expected in the next year compared to the current price of 2.46. Check the ORCHESTRA BIOMED HOLDINGS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ORCHESTRA BIOMED HOLDINGS IN worth?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a market capitalization of 94.24M USD. This makes OBIO a Micro Cap stock.


How many employees does ORCHESTRA BIOMED HOLDINGS IN have?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) currently has 56 employees.


What are the support and resistance levels for ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a resistance level at 2.62. Check the full technical report for a detailed analysis of OBIO support and resistance levels.


Is ORCHESTRA BIOMED HOLDINGS IN (OBIO) expected to grow?

The Revenue of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is expected to decline by -11.18% in the next year. Check the estimates tab for more information on the OBIO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock pay dividends?

OBIO does not pay a dividend.


When does ORCHESTRA BIOMED HOLDINGS IN (OBIO) report earnings?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) will report earnings on 2025-05-09, after the market close.


What is the Price/Earnings (PE) ratio of ORCHESTRA BIOMED HOLDINGS IN (OBIO)?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).


What is the Short Interest ratio of ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

The outstanding short interest for ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 2.16% of its float. Check the ownership tab for more information on the OBIO short interest.


OBIO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

OBIO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to OBIO. OBIO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OBIO Financial Highlights

Over the last trailing twelve months OBIO reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -10.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -80.11%
ROE -185.16%
Debt/Equity 0.43
Chartmill High Growth Momentum
EPS Q2Q%-13.51%
Sales Q2Q%-3.44%
EPS 1Y (TTM)-10.67%
Revenue 1Y (TTM)-4.49%

OBIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to OBIO. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -22.12% and a revenue growth -11.18% for OBIO


Ownership
Inst Owners43.2%
Ins Owners4.1%
Short Float %2.16%
Short Ratio1.48
Analysts
Analysts84.62
Price Target15.15 (515.85%)
EPS Next Y-22.12%
Revenue Next Year-11.18%